Novavax (NASDAQ: NVAX)

Novavax is releasing earnings tomorrow morning, with an estimate EPS of minus $0.11

NVAX is the heaviest title in the $NNZ (Merrill Lynch Nanotech Index) and should affect the performance of the nanotechnology sector, even if it really is a biopharmaceutical company.

Some technology used by Nanovax can still be included in the nanotech field, and future developments, like retro-viruses and new vaccine deployment techniques can very well be included in the nanotechnology area.

NVAX is heading higher today with good volume, with probably some investors already making a bet to what the results will be tomorrow.



Novavax's Net Income is getting better year after year and we might get a surprise in the next months.
The chart looks bullish for the end of this year, and should continue this uptrend if there are no bad results tomorrow.

Some recent news about Nanovax:
Novavax's Pandemic Influenza Vaccine Candidates Trigger Robust Immune Response In Pre-Clinical Models